Citius Pharmaceuticals’ Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...
The Pharma Letter2d
Merck's Keytruda and Citius' Lymphir combo trial shows promising results
Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...
Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Moderna Chief Human Resources Officer Tracey Franklin has expanded her role to Chief People and Digital Technology Officer, overseeing the Company's talent and digital functions. Brad Miller, Chief ...
Merck: An Undervalued Dividend Machine
Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...